<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02556944</url>
  </required_header>
  <id_info>
    <org_study_id>2015-02-001-009</org_study_id>
    <nct_id>NCT02556944</nct_id>
  </id_info>
  <brief_title>Mix and Match Study of Two Multifocal Intraocular Lens With Different Add Power</brief_title>
  <official_title>Mix and Match Study of Two Multifocal Intraocular Lens With Different Add Power</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>tae-young chung</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess postsurgical visual acuity (distant, intermediate, near), refractive errors,&#xD;
      contrast sensitivity, visual function and patient satisfaction after implantation of&#xD;
      multifocal IOLs of different add power contralaterally.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multifocal intraocular lens (MIOL) is considered a prevailing alternative to restore the&#xD;
      functional vision from far to near independent of glasses. Many clinical studies on&#xD;
      diffractive MIOLs, refractive MIOLs, or hybrid MIOLs in enhancing quality of vision showed&#xD;
      promising outcomes. Several studies have confirmed the satisfactory visual outcomes of Tecnis&#xD;
      MIOL with +4.00 D add power. The purpose of study is to assess the visual performance after&#xD;
      cataract surgery with bilateral implantation of multifocal IOL with two different add power&#xD;
      (+2.75 D or +3.25 D) in one patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity(Distant, intermediate, near)</measure>
    <time_frame>1month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity(Distant, intermediate, near)</measure>
    <time_frame>3month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>Mix and matched patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mix and matched patients will get phacoemulsification with multifocal intraocular lens implantation with two different add power (+2.75 diopters (D) or +3.25 D, respectively) in each eye of a patient, contralaterally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Phacoemulsification with multifocal intraocular lens</intervention_name>
    <description>Phacoemulsification and implantation of a multifocal intraocular lens (IOL) with two different add power (+2.75 diopters (D) or +3.25 D, respectively) in each eye of a patient, contralaterally. They're called mix and matched patients.</description>
    <arm_group_label>Mix and matched patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Age-related cataract&#xD;
&#xD;
               -  Adult at the age of 21 or older at the time of the pre-operative examination and&#xD;
                  willing to have surgery on their 2nd eye within 7-28 days of their 1st eye.&#xD;
&#xD;
               -  A patient has the visual potential of 20/25 or better in each eye after cataract&#xD;
                  removal and IOL implantation.&#xD;
&#xD;
               -  A patient with preoperative corneal astigmatism from IOL Master less than 1&#xD;
                  diopters&#xD;
&#xD;
               -  Written informed consent to surgery and participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Pregnant woman and lactating woman&#xD;
&#xD;
               -  A patient with history of retinal disease&#xD;
&#xD;
               -  A patient with history of ocular trauma or ocular surgery (Intraocular surgery,&#xD;
                  refractive surgery, ocular surface surgery) in either eye&#xD;
&#xD;
               -  A patient with evidence of keratoconus or significant irregular astigmatism on&#xD;
                  pre-operative topography in either eye.&#xD;
&#xD;
               -  A patient that has been wearing PMMA lenses within 6 months, gas permeable lenses&#xD;
                  within one month, or extended -wear or daily soft contact lens within 7 days of&#xD;
                  their scheduled surgery.&#xD;
&#xD;
               -  Those with other diseases that can affect capsule stability such as&#xD;
                  pseudoexoliation syndrome, glaucoma, traumatic cataract, or marfan syndrome&#xD;
&#xD;
               -  Those who are not able to read and understand the informed consent (illiterate or&#xD;
                  foreigners)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tae-Young Chung, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>September 21, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <last_update_submitted>September 21, 2015</last_update_submitted>
  <last_update_submitted_qc>September 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>tae-young chung</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Depth of focus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

